CN106047934B - 一种多编码框、非整合型慢病毒载体的构建和应用 - Google Patents
一种多编码框、非整合型慢病毒载体的构建和应用 Download PDFInfo
- Publication number
- CN106047934B CN106047934B CN201610651245.XA CN201610651245A CN106047934B CN 106047934 B CN106047934 B CN 106047934B CN 201610651245 A CN201610651245 A CN 201610651245A CN 106047934 B CN106047934 B CN 106047934B
- Authority
- CN
- China
- Prior art keywords
- region
- car
- ires
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims abstract description 77
- 238000010276 construction Methods 0.000 title abstract description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 238000010367 cloning Methods 0.000 claims abstract description 30
- 230000014509 gene expression Effects 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 230000003612 virological effect Effects 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 238000009169 immunotherapy Methods 0.000 claims abstract description 9
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 4
- 208000016361 genetic disease Diseases 0.000 claims abstract description 4
- 238000009168 stem cell therapy Methods 0.000 claims abstract description 4
- 238000009580 stem-cell therapy Methods 0.000 claims abstract description 4
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 25
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 25
- 101150036449 SIRPA gene Proteins 0.000 claims description 22
- 230000008685 targeting Effects 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 11
- 241001529936 Murinae Species 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 230000006690 co-activation Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 9
- 230000003248 secreting effect Effects 0.000 claims description 9
- 102000015728 Mucins Human genes 0.000 claims description 7
- 108010063954 Mucins Proteins 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000009466 transformation Effects 0.000 claims description 6
- 239000012636 effector Substances 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims description 4
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 claims description 3
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 claims description 3
- 210000000299 nuclear matrix Anatomy 0.000 claims description 3
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 4
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 abstract description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 238000002659 cell therapy Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000001415 gene therapy Methods 0.000 abstract description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract description 2
- 230000035515 penetration Effects 0.000 abstract description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 55
- 239000013612 plasmid Substances 0.000 description 36
- 241000700605 Viruses Species 0.000 description 25
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 22
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 22
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 230000010354 integration Effects 0.000 description 13
- 231100000433 cytotoxic Toxicity 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000001472 cytotoxic effect Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 241000713666 Lentivirus Species 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 108010062802 CD66 antigens Proteins 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 210000004322 M2 macrophage Anatomy 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 102000044459 human CD47 Human genes 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000000131 Beta tubulin Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 description 1
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710116852 Molybdenum cofactor sulfurase 1 Proteins 0.000 description 1
- 101710116850 Molybdenum cofactor sulfurase 2 Proteins 0.000 description 1
- 102000007298 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 101100545229 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ZDS2 gene Proteins 0.000 description 1
- 101001000154 Schistosoma mansoni Phosphoglycerate kinase Proteins 0.000 description 1
- 101100113084 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcs2 gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 101100167209 Ustilago maydis (strain 521 / FGSC 9021) CHS8 gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical class C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000004707 mucinous cystadenoma Diseases 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000010469 pro-virus integration Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610651245.XA CN106047934B (zh) | 2016-08-09 | 2016-08-09 | 一种多编码框、非整合型慢病毒载体的构建和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610651245.XA CN106047934B (zh) | 2016-08-09 | 2016-08-09 | 一种多编码框、非整合型慢病毒载体的构建和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106047934A CN106047934A (zh) | 2016-10-26 |
CN106047934B true CN106047934B (zh) | 2020-04-07 |
Family
ID=57481685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610651245.XA Active CN106047934B (zh) | 2016-08-09 | 2016-08-09 | 一种多编码框、非整合型慢病毒载体的构建和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106047934B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018152033A1 (en) * | 2017-02-14 | 2018-08-23 | Promab Biotechnologies, Inc. | Cd47-car-t cells |
CN109554348A (zh) * | 2017-09-27 | 2019-04-02 | 亘喜生物科技(上海)有限公司 | 可诱导分泌抗cd47抗体的工程化免疫细胞 |
CN110129369B (zh) * | 2018-02-09 | 2023-10-13 | 上海交通大学医学院附属上海儿童医学中心 | 一种嵌合抗原受体基因工程载体、免疫细胞及其应用 |
CN109554433B (zh) * | 2018-12-29 | 2022-04-29 | 杭州科兴生物科技有限公司 | 一种基于CD47/SIRPα阻断功能及其生物效应的药物快速筛选方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102344939A (zh) * | 2010-07-23 | 2012-02-08 | 聂凌云 | 一种抑制内源靶基因的同时能表达外源基因的多功能慢病毒载体 |
-
2016
- 2016-08-09 CN CN201610651245.XA patent/CN106047934B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102344939A (zh) * | 2010-07-23 | 2012-02-08 | 聂凌云 | 一种抑制内源靶基因的同时能表达外源基因的多功能慢病毒载体 |
Non-Patent Citations (4)
Title |
---|
S/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection;Santhosh Chakkaramakkil Verghese et al.;《Nucleic Acids Research》;20140127;第42卷(第7期);第e53页 * |
Santhosh Chakkaramakkil Verghese et al..S/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection.《Nucleic Acids Research》.2014,第42卷(第7期),第e53页. * |
戴冰冰 等.核骨架基质结合区(S MAR)提高逆转录病毒载体介导egfp 在NIH3T3 细胞中的表达.《中国生物化学与分子生物学报》.2003,第19卷(第1期), * |
核骨架基质结合区(S MAR)提高逆转录病毒载体介导egfp 在NIH3T3 细胞中的表达;戴冰冰 等;《中国生物化学与分子生物学报》;20030228;第19卷(第1期);第24-30页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106047934A (zh) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106047934B (zh) | 一种多编码框、非整合型慢病毒载体的构建和应用 | |
CN108373504B (zh) | Cd24特异性抗体和抗cd24-car-t细胞 | |
EP3505631A1 (en) | Human pd-1 knockdown sirna, recombinant expression car-t vector, preparation method thereof, and application of same | |
Matsuda et al. | Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine | |
CN110863013A (zh) | 改进的治疗性t细胞 | |
CN107033248B (zh) | 识别癌胚抗原的嵌合抗原受体及其应用 | |
EP3550024A1 (en) | Pd-l1 knockout car-t transgenic vector for suppressing immune escape, preparation method thereof, and application of same | |
CN112979828A (zh) | 靶向cld18a2的t淋巴细胞及其制备方法和应用 | |
CN114127109B (zh) | 靶向Claudin18.2的抗体或嵌合抗原受体 | |
CN111212903A (zh) | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 | |
CN113621582B (zh) | 联合表达CCR2b的工程化免疫细胞及其制备和应用 | |
EP3704136A1 (en) | Adapter-based retroviral vector system for the selective transduction of target cells | |
CN111748044B (zh) | Cd19和pd-l1双靶点嵌合抗原受体及其应用 | |
KR20070004026A (ko) | 선택적 스플라이싱을 이용하여 진핵 세포에서 폴리펩티드다량체를 발현하기 위한 방법 및 구축물 | |
RU2770002C2 (ru) | Химерный антигенный рецептор | |
CN109844125A (zh) | 人pd-1基因敲除的cldn18.2特异性嵌合抗原受体t细胞的制备方法以及应用 | |
US20050158712A1 (en) | Methods for purifying viral particles for gene therapy | |
CN113717288A (zh) | 逆转肿瘤微环境的融合蛋白及其应用 | |
WO2012095535A1 (en) | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scfv) | |
EP2039766A1 (en) | Immunocompetent cell having anti-cd38 antibody on its cell surface | |
CN110863014A (zh) | 改进的慢病毒载体 | |
Matano et al. | trans-Dominant interference with virus infection at two different stages by a mutant envelope protein of Friend murine leukemia virus | |
CN108456662B (zh) | 针对肝癌相关抗原dlk1为靶点的car-t构建方法 | |
CN111704674A (zh) | 一种靶向c-Met且自分泌PD-L1 scFv的嵌合抗原受体及其应用 | |
CN110669138A (zh) | 一种双嵌合抗原受体、t细胞及其构建方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231218 Address after: 510000 room 508, building C6, room 509, building C6, No. 11, Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangzhou Xiling Biotechnology Co.,Ltd. Address before: 300457 No.29, 13th Street, economic and Technological Development Zone, Tanggu District, Tianjin Patentee before: Li Yinchuan |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Construction and application of a multi coding box, non integrated lentiviral vector Granted publication date: 20200407 Pledgee: Bank of China Limited Guangzhou Yuexiu Branch Pledgor: Guangzhou Xiling Biotechnology Co.,Ltd. Registration number: Y2024980039445 |